U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice voted to ...